(ADPT), Microsoft Corporation (NASDAQ:MSFT) - Adaptive Biote

(ADPT), Microsoft Corporation (NASDAQ:MSFT) - Adaptive Biotechnologies Secures FDA EUA For COVID-19 T-Cell Response Test


This T cell-based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with 
Microsoft Corporation (NASDAQ: MSFT).
Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection.
The EUA was issued based on a clinical validation study demonstrating a sensitivity of 97.1% from the date of COVID-19 diagnosis with RT-PCR. The test also showed a specificity of 100%.
The FDA noted that the test should not be used to diagnose current SARS-CoV-2 infection.

Related Keywords

, Microsoft Corporation , Adaptive Biotechnologies Corp , Emergency Use Authorization , Antigen Map , மைக்ரோசாஃப்ட் நிறுவனம் , மாற்றி அமைக்கத்தக்க உயிரி தொழில்நுட்பங்கள் கார்ப் , அவசரம் பயன்பாடு அங்கீகாரம் ,

© 2025 Vimarsana